Aptose Biosciences (APTO)
(Real Time Quote from BATS)
$0.48 USD
0.00 (-0.21%)
Updated Aug 15, 2024 12:26 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Aptose Biosciences (APTO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$10.33 | $18.00 | $6.00 | 2,052.08% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Aptose Biosciences comes to $10.33. The forecasts range from a low of $6.00 to a high of $18.00. The average price target represents an increase of 2% from the last closing price of $0.48.
Analyst Price Targets (3 )
Broker Rating
Aptose Biosciences currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on three recommendations.
Of the three recommendations deriving the current ABR, two are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 66.67% and 33.33% of all recommendations. A month ago, Strong Buy made up 66.67%, while Buy represented 33.33%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/APTO.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 3 | 3 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.33 | 1.33 | 1.33 | 1.25 | 1.25 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/1/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
3/27/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
3/27/2024 | Canaccord Genuity | John L Newman | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.33 |
ABR (Last week) | 1.33 |
# of Recs in ABR | 3 |
Average Target Price | $10.33 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 80 of 253 |
Current Quarter EPS Est: | -0.64 |